Mass General Brigham Validates New Genetic Test Predicting Risk for Eight Cardiovascular Conditions

Mass General Brigham researchers validate a DNA-based tool that identifies high genetic risk for coronary artery disease and seven other cardiac conditions.

By: AXL Media

Published: Apr 30, 2026, 9:56 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Genomic Breakthrough in Preventive Cardiology

Clinical investigators at the Mass General Brigham Heart and Vascular Institute have successfully validated a sophisticated genetic screening tool designed to forecast a patient’s inherited susceptibility to eight distinct cardiovascular ailments. This integrated polygenic risk score, or PRS, functions by synthesizing data from numerous genetic variants into a singular, actionable report. According to the study findings, the tool provides a comprehensive diagnostic lens that extends beyond traditional risk factors like blood pressure or cholesterol levels, which frequently fail to identify individuals harboring deep-seated genetic predispositions.

Refining the Predictive Accuracy of DNA Analysis

The development of this tool involved a rigorous training phase utilizing health and genomic data from 245,000 participants within the National Institutes of Health’s All of Us Research Program. To ensure the reliability of the results, researchers subsequently validated the model using data from 53,000 patients enrolled in the Mass General Brigham Biobank. The statistical outcomes were stark, revealing that individuals scoring in the top 10 percent for genetic risk were 3.7 times more likely to suffer from coronary artery disease than those with an average genetic profile.

Bridging the Gap Between Research and Bedside Care

A primary objective of the initiative was to translate complex molecular data into a format that is easily interpreted by both medical professionals and their patients. The resulting reports utilize intuitive vascular health graphs that compare an individual’s risk against the broader population. According to Pradeep Natarajan, the Director of Preventive Cardiology at Mass General Brigham, providing a clear and patient-friendly genetic risk report was essential for the successful integration of DNA interpretation into standard clinical practice.